Clinical Trials Browser

Completed × Triple Negative Breast Neoplasms × Everolimus × Clear all

NCT02456857 2024-02-13

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Phase 2 Completed

17 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Phase 1 Completed

BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

NCT02120469 2022-07-05

Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer

Phase 1 Completed

27 enrolled 16 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01931163 2021-07-20

NECTAR

Phase 2 Completed

24 enrolled 7 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01031446 2018-08-31

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

55 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00930930 2015-05-07

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Completed

145 enrolled 10 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms